--- title: "Biocon Biologics’ share of India’s trastuzumab and bevacizumab markets will increase at the cost of Roche." description: "The Supreme Court’s September 22 criticism of excessive cancer-drug prices increases pressure on the National Pharmaceutical Pricing Authority to expand limits on the margins charged on patented cance" url: "https://bilby.ai/predictions/p/119/biocon-biologics-share-of-india-s-trastuzumab-and-bevacizumab-markets-will-incre" markdown: "https://bilby.ai/predictions/p/119/biocon-biologics-share-of-india-s-trastuzumab-and-bevacizumab-markets-will-incre.md" index: "https://bilby.ai/llms.txt" --- > For agents: Bilby answers questions about what governments do, from documents collected at source and checked by research analysts. To ask Bilby yourself, connect to its MCP server at https://pulse.bilby.ai/mcp (setup: https://docs.bilby.ai/developers/mcp-server). Every page on this site is also markdown: add .md to its address, or send Accept: text/markdown. https://bilby.ai/llms.txt lists them all. # Biocon Biologics’ share of India’s trastuzumab and bevacizumab markets will increase at the cost of Roche. - **Made:** 23 Sep 2026 - **By:** Owen Bae - **Market:** India - **Outcome:** Unresolved The Supreme Court’s September 22 criticism of excessive cancer-drug prices increases pressure on the National Pharmaceutical Pricing Authority to expand limits on the margins charged on patented cancer medicines. Roche’s Herceptin (trastuzumab) and Avastin (bevacizumab) are among the most likely early targets because both drugs have faced price disputes in India and already compete with established domestic generic alternatives, CANMAb and Abevmy from Biocon. As margin caps squeeze profits, foreign suppliers will struggle to match the production scale of domestic generic manufacturers. Better able to sustain high volumes at lower margins, domestic generics producers are therefore positioned to gain market share. Roche therefore faces the most immediate exposure, while AstraZeneca, Novartis and Bristol Myers Squibb face less risk because their leading patented cancer drugs do not yet have established Indian biosimilar competitors. [Ask Bilby about this prediction](https://pulse.bilby.ai/?prompt=Biocon%20Biologics%E2%80%99%20share%20of%20India%E2%80%99s%20trastuzumab%20and%20bevacizumab%20markets%20will%20increase%20at%20the%20cost%20of%20Roche.) ## Ask Bilby about it Carry the prediction into a question: what has changed since, who decides, and who is exposed. - [What has changed since it was made?](https://pulse.bilby.ai/?prompt=What%20has%20changed%20since%20Bilby%20predicted%20this%3F%20Biocon%20Biologics%E2%80%99%20share%20of%20India%E2%80%99s%20trastuzumab%20and%20bevacizumab%20markets%20will%20increase%20at%20the%20cost%20of%20Roche.) - [Who decides whether it happens?](https://pulse.bilby.ai/?prompt=Who%20decides%20whether%20this%20happens%3F%20Biocon%20Biologics%E2%80%99%20share%20of%20India%E2%80%99s%20trastuzumab%20and%20bevacizumab%20markets%20will%20increase%20at%20the%20cost%20of%20Roche.) - [Who gains and who loses if it does?](https://pulse.bilby.ai/?prompt=Who%20gains%20and%20who%20loses%20if%20this%20happens%3F%20Biocon%20Biologics%E2%80%99%20share%20of%20India%E2%80%99s%20trastuzumab%20and%20bevacizumab%20markets%20will%20increase%20at%20the%20cost%20of%20Roche.) ## More from India 18 predictions on India so far, newest first. - 29 Oct 2026 · [Reliance Industries’ diesel export margins will come under pressure in 2027, putting roughly US$6 billion in annual gross profit at risk.](https://bilby.ai/predictions/p/195/reliance-industries-diesel-export-margins-will-come-under-pressure-in-2027-putti) · Unresolved - 15 Oct 2026 · [India will avoid new US tariffs under the Graham Act when President Trump makes his decision on 18 October.](https://bilby.ai/predictions/p/167/india-will-avoid-new-us-tariffs-under-the-graham-act-when-president-trump-makes-) · True - 14 Oct 2026 · [India’s state-owned power producer NTPC will fail to secure binding green ammonia or methanol export contracts by the end of 2027, forgoing US$120 million a year in export premiums.](https://bilby.ai/predictions/p/163/india-s-state-owned-power-producer-ntpc-will-fail-to-secure-binding-green-ammoni) · Unresolved [All 18 from India](https://bilby.ai/predictions/log?tag=india) · Marked true or false when each resolves ## See what we’re seeing next. New predictions in the Asia Daily Take, free every weekday, and in Bilby whenever you have a question. [Get the Asia Daily Take](https://bilby.ai/asia#asia-daily-take) · [Try Bilby](https://pulse.bilby.ai/sign-up)